Pieris Pharmaceuticals, Inc. Annual report [Section 13 and 15(d), not S-K Item 405]

Fair Value Measurements - Additional Information (Details) $ in Thousands	Dec. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)	Nov. 30, 2023 USD ($)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liabilities - royalty agreement	$ 1,647	$ 1,014
Recurring Basis [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liabilities - royalty agreement	$ 1,647	$ 1,014	$ 7,800
Net Sales Discount Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative, assumption			0.21
Discount rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative, assumption	0.20	0.25	0.22
Weighted Average Cost of Capital [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative, assumption			0.245